Loading Events

« All Events

  • This event has passed.

Web-based launch: The NEW GARDskin Dose-Response

June 17

If you’re interested in quantitative potency assessment of your product, listen in and learn how GARDskin Dose-Response threshold concentrations can be linked to LLNA´s EC3 values and human sensitizing potency.

What You Will Learn

In this webinar, attendees will gain insights into:

  • How GARDskin Dose-Response studies provide information to establish safety thresholds for different substances.
  • How the threshold concentrations correlate with LLNA’s EC3 values and human sensitizing potency.
  • Examples of how the readout can be used depending on the customer specific needs.

 

Featured Speaker

Andy Forreryd, PhD, SenzaGen AB

High information, high accuracy

The GARD tests are developed by combining genomic data from a relevant human cell type with machine learning to create a prediction model for identification of chemical sensitizers. This holistic, cell-based, high-information approach provides prediction accuracy exceeding 90% for skin sensitization.

With its high accuracy, demonstrated human relevance and broad applicability, the GARD assay platform can support your specific test requirements.

Details

Date:
June 17

Venue

4.00pm CEST | 10.00am EDT

Details

Date:
June 17

Venue

4.00pm CEST | 10.00am EDT